Literature DB >> 11453057

Imaging of the dopaminergic system in parkinsonism with SPET.

K Tatsch1.   

Abstract

Parkinsonism is a feature of various neurodegenerative diseases. Since it is well known that the dopaminergic system plays a major role in parkinsonism, numerous reports have focused on the assessment of the dopaminergic system in vivo. While the use of positron emission tomography (PET) for routine application is still hampered by its limited availability, single photon emission tomography (SPET) has been shown to deliver comparable results to PET in clinical settings. In recent years SPET investigations of the dopamine transporter and of the dopamine D2-like receptors have provided valuable information about the pre- and postsynaptic dopaminergic system in parkinsonism. This article briefly reviews the literature dealing with SPET imaging in parkinsonism and specifically addresses the ligands used, the methodology applied, and the current major clinical applications.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11453057     DOI: 10.1097/00006231-200107000-00015

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  8 in total

1.  Can SPET imaging of dopamine uptake sites replace PET imaging in Parkinson's disease? For.

Authors:  Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2002-03-23       Impact factor: 9.236

2.  Partial volume effect correction in SPECT for striatal uptake measurements in patients with neurodegenerative diseases: impact upon patient classification.

Authors:  Marine Soret; Pierre Malick Koulibaly; Jacques Darcourt; Irène Buvat
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-04-26       Impact factor: 9.236

3.  Quantitative evaluation of simultaneous reconstruction with model-based crosstalk compensation for 99mTc/123I dual-isotope simultaneous acquisition brain SPECT.

Authors:  Yong Du; Eric C Frey
Journal:  Med Phys       Date:  2009-06       Impact factor: 4.071

4.  Lower striatal dopamine transporter binding in neuroleptic-naive schizophrenic patients is not related to antipsychotic treatment but it suggests an illness trait.

Authors:  Jose J Mateos; Francisco Lomeña; Eduard Parellada; Font Mireia; Emili Fernandez-Egea; Javier Pavia; Alberto Prats; Francisca Pons; Miquel Bernardo
Journal:  Psychopharmacology (Berl)       Date:  2006-09-22       Impact factor: 4.530

5.  Iterative reconstruction with correction of the spatially variant fan-beam collimator response in neurotransmission SPET imaging.

Authors:  Deborah Pareto; Albert Cot; Javier Pavía; Carles Falcón; Ignacio Juvells; Francisco Lomeña; Domènec Ros
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-07-03       Impact factor: 9.236

6.  EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2.

Authors:  Jacques Darcourt; Jan Booij; Klaus Tatsch; Andrea Varrone; Thierry Vander Borght; Ozlem L Kapucu; Kjell Någren; Flavio Nobili; Zuzana Walker; Koen Van Laere
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02       Impact factor: 9.236

7.  Involvement of nigrostriatal pathway in Japanese encephalitis with movement disorders: evidence from 99mTc-TRODAT-1 and 123I-IBZM SPECT imagings.

Authors:  Chang-Hsu Liao; Zaodung Ling; Chung-Hsing Chou; Wen-Sheng Huang; Jong-Chyou Denq; Jiann-Chyun Lin; Cheng-Yu Chen; Chia-Jung Chang; Giia-Sheun Peng
Journal:  Mol Imaging Biol       Date:  2009-06-23       Impact factor: 3.488

8.  Does combined imaging of the pre- and postsynaptic dopaminergic system increase the diagnostic accuracy in the differential diagnosis of parkinsonism?

Authors:  Walter Koch; Christine Hamann; Perry E Radau; Klaus Tatsch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-02-21       Impact factor: 10.057

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.